USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Targeted Nanoparticle Delivery Agent for Treatment of Adult…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
1143342
Solicitation Year:
2012
Solicitation Topic Code:
NM
Solicitation Number:
Small Business Information
NanoValent Pharmaceuticals, Inc.
910 Technology BLVD STE G Bozeman, MT 59718-4012
View profile »
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2012
Title: SBIR Phase I: Targeted Nanoparticle Delivery Agent for Treatment of Adult Leukemia
Agency: NSF
Contract: 1143342
Award Amount: $149,848.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project aims to explore the application of a targeted nanodelivery system for both treatment and efficacy monitoring in patients with adult leukemia. Unlike solid tumors, for which surgery, radiation, and conventional treatments are an option, leukemias are cancers of the blood, which have very poor prognosis due to the fact that they are disseminated diseases from inception. In this project, the targeted and drug-filled nanoparticle will be optimized for effective tumor killing in cell culture, followed by validation using established in-vivo methods for adult leukemia in a mouse model. It is expected that this targeted nanodelivery system will increase the therapeutic window and minimize systemic therapy related toxicity, demonstrating the superior margin of safety compared to the standard methods for treatment. The broader/commercial impact of this project will be the potential to provide a technology that is capable of delivering a wide array of drug molecules (hydrophilic and hydrophobic) or drug cocktails using multiple tissue targeting ligands. The specific focus of this project is adult acute leukemia for which there is currently no curative treatment, and the adult survival rate is only 30%. Highly robust, customizable, stable, and easy to manufacture, this particle delivery system is anticipated to make a major impact on the treatment of adult leukemia.

Principal Investigator:

Jon O. Nagy
4065868420
jon.nagy@nagyconsult.com

Business Contact:

Jon O. Nagy
4065868420
jon.nagy@nagyconsult.com
Small Business Information at Submission:

NanoValent Pharmaceuticals, Inc.
910 Technology BLVD STE G Bozeman, MT 59718-4012

EIN/Tax ID: 205342640
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: Yes